bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 1,934 shares, an increase of 334.6% from the September 15th total of 445 shares. Based on an average daily volume of 2,441 shares, the days-to-cover ratio is presently 0.8 days.
bioAffinity Technologies Trading Down 24.9%
NASDAQ:BIAFW traded down $0.14 on Monday, hitting $0.43. The stock had a trading volume of 270 shares, compared to its average volume of 5,096. bioAffinity Technologies has a 1 year low of $0.05 and a 1 year high of $0.98. The firm’s fifty day simple moving average is $0.25 and its two-hundred day simple moving average is $0.23.
About bioAffinity Technologies
bioAffinity Technologies, Inc is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses proprietary porphyrin-based compounds designed to selectively interact with cancer cells and support their detection or treatment.
Its lead diagnostic product, CyPath Lung, is a noninvasive urine test intended to aid in the detection of lung cancer. The test uses a porphyrin compound delivered in nanoparticles and analyzed through fluorescence-based methods.
Further Reading
- Five stocks we like better than bioAffinity Technologies
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
- Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
